TITLE

Single dose of Glycoprotein K (gK)-deleted HSV-1 live-attenuated virus protects mice against lethal vaginal challenge with HSV-1 and HSV-2 and induces lasting T cell memory immune responses

AUTHOR(S)
Iyer, Arun V.; Pahar, Bapi; Chouljenko, Vladimir N.; Walker, Jason D.; Stanfield, Brent; Kousoulas, Konstantin G.
PUB. DATE
November 2013
SOURCE
Virology Journal;2013, Vol. 10 Issue 1, p2
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background Herpes simplex virus type-1(HSV-1) and HSV-2 are important human pathogens that cause significant ocular and urogenital complications, respectively. We have previously shown that HSV-1 virions lacking glycoprotein K (gK) are unable to enter into neurons via synaptic axonal membranes and be transported in either retrograde or anterograde manner. Here, we tested the ability of HSV-1 (F) gK-null to protect against lethal challenge with either highly virulent ocular HSV-1 (McKrae strain), or genital HSV-2 (G strain). The gK-null virus vaccine efficiently protected mice against lethal vaginal infection with either HSV- 1(McKrae) or HSV-2 (G). Results Female mice were immunized via a single intramuscular injection with 106 PFU of the gKnull virus. Immunized mice were treated with Depo-Provera fourteen days after vaccination and were challenged via the vaginal route one week later. Ninety percent of mice vaccinated with the gK-null virus survived HSV-1 (McKrae) challenge, while 70% of these mice survived after HSV-2 (G) challenge. Moreover, all vaccinated mice exhibited substantially reduced disease symptoms irrespective of HSV-1 or HSV-2 challenge as compared to the mock vaccinated challenge group. T-cell memory immune responses to specific glycoprotein B (gB) and glycoprotein D (gD) peptide epitopes were detectable at 7 months post vaccination. Conclusions These results suggest that the highly attenuated, non-neurotropic gK-null virus may be used as an effective vaccine to protect against both virulent HSV-1 and HSV-2 genital infections and induce lasting immune responses.
ACCESSION #
91841470

 

Related Articles

  • Cross-presentation and genome-wide screening reveal candidate T cells antigens for a herpes simplex virus type 1 vaccine. Lichen Jing; Haas, Jürgen; Chong, Tiana M.; Bruckner, Joseph J.; Dann, Greg C.; Lichun Dong; Marshak, Joshua O.; McClurkan, Christopher L.; Yamamoto, Tori N.; Bailer, Susanne M.; Laing, Kerry J.; Wald, Anna; Verjans, Georges M. G. M.; Koelle, David M. // Journal of Clinical Investigation;Feb2012, Vol. 122 Issue 2, p654 

    Herpes simplex virus type 1 (HSV-1) not only causes painful recurrent oral-labial infections, it can also cause permanent brain damage and blindness. There is currently no HSV-1 vaccine. An effective vaccine must stimulate coordinated T cell responses, but the large size of the genome and the...

  • Activation and Evasion of Innate Antiviral Immunity by Herpes Simplex Virus. Melchjorsen, Jesper; Matikainen, Sampsa; Paludan, Søren R. // Viruses (1999-4915);Dec2009, Vol. 1 Issue 3, p727 

    Herpes simplex virus (HSV), a human pathogenic virus, has evolved several strategies to evade the production and function of interferons (IFNs) and cytokines generated by the innate immune system to restrict the virus. Equilibrium exists between the virus and the immune response, and a shift in...

  • The Herpes Simplex Virus 1-Encoded Envelope Glycoprotein B Activates NF-κB through the Toll-Like Receptor 2 and MyD88/TRAF6-Dependent Signaling Pathway. Mingsheng Cai; Meili Li; Kezhen Wang; Shuai Wang; Qiong Lu; Jinghua Yan; Mossman, Karen L.; Rongtuan Lin; Chunfu Zheng // PLoS ONE;Jan2013, Vol. 8 Issue 1, Special section p1 

    The innate immune response plays a critical role in the host defense against invading pathogens, and TLR2, a member of the Toll-like receptor (TLR) family, has been implicated in the immune response and initiation of inflammatory cytokine secretion against several human viruses. Previous studies...

  • Genocea Unveils Protective Therapeutic Vaccine for Herpes Simplex Virus Type 2.  // Biomedical Market Newsletter;8/7/2012, Vol. 21, p1 

    The article informs that Genocea Biosciences Inc. will present a data on developing a therapeutic vaccine for Herpes Simplex Virus type 2 (HSV-2) at the 37th annual International Herpesvirus Workshop (IHW) to be held in Calgary, Alberta. It discusses the data which provides information on...

  • Plasmid DNA--Expressed Secreted and Nonsecreted Forms of Herpes Simplex Virus Glycoprotein D2... Higgins, Terry J.; Herold, Kathleen M.; Arnold, Renee L.; McElhiney, Susan P.; Shroff, Khushroo E.; Pachuk, Catherine J. // Journal of Infectious Diseases;11/1/2000, Vol. 182 Issue 5, p1311 

    Reveals that plasmid DNA-expressed secreted and nonsecreted forms of herpes simplex virus glycoprotein D2 induce different types of immune responses. Modulation of immune response by expression of varied forms of an antigen; Difference in cellular localization of antigens.

  • Mucosal Herpes Immunity and Immunopathology to Ocular and Genital Herpes Simplex Virus Infections. Chentoufi, Aziz Alami; Ben Mohamed, Lbachir // Clinical & Developmental Immunology;2012, p1 

    Herpes simplex viruses type 1 and type 2 (HSV-1 and HSV-2) are amongst the most common human infectious viral pathogens capable of causing serious clinical diseases at every stage of life, from fatal disseminated disease in newborns to cold sores genital ulcerations and blinding eye disease....

  • CTL response compensation for the loss of an immunodominant class I-restricted HSV-1 determinant. STOCK, ANGUS T.; JONES, CLAERWEN M.; HEATH, WILLIAM R.; CARBONE, FRANCIS R. // Immunology & Cell Biology;Dec2006, Vol. 84 Issue 6, p543 

    The T-cell response to even complex pathogens is often focused on only a handful of immunodominant determinants. Such narrow responses provoke a selective pressure that can drive the emergence of CTL escape variants, raising the question of whether a broader response, targeting multiple...

  • Expression of Cutaneous Lymphocyte-Associated Antigen and E-selectin Ligand by Circulating Human Memory CD4+ T Lymphocytes Specific for Herpes Simplex Virus Type 2. Gonzalez, Julio C.; Kwok, William W.; Wald, Anna; McClurkan, Christopher L.; Huang, Jay; Koelle, David M. // Journal of Infectious Diseases;1/15/2005, Vol. 191 Issue 2, p243 

    Virus-specific memory T lymphocytes traffic to sites of viral infection. Herpes simplex virus (HSV) type 2-specific CD4+ and CD8+ T lymphocytes differ with regard to their homing kinetics to infected tissues. We studied the expression of cutaneous lymphocyte-associated antigen (CLA) and...

  • Early Events in Herpes Simplex Virus Lifecycle with Implications for an Infection of Lifetime. Salameh, Sarah; Sheth, Urmi; Shukla, Deepak // Open Virology Journal;2012, Vol. 6, p1 

    Affecting a large percentage of human population herpes simplex virus (HSV) types -1 and -2 mainly cause oral, ocular, and genital diseases. Infection begins with viral entry into a host cell, which may be preceded by viral "surfing" along filopodia. Viral glycoproteins then bind to one or more...

Share

Read the Article

Courtesy of NEW JERSEY STATE LIBRARY

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics